TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide
TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets. Teriflunomide is an…
AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)
On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is…
TIEFENBACHER PHARMACEUTICALS Announces Global Launch Of Rivaroxaban
TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…
International Brand Relaunch of Tiefenbacher Group
“We are very excited to launch the new Tiefenbacher Group website. It represents the fundamental changes which we have started in the recent years. We are on the move to drive important…
Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…